The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Replagal agalsidase alfa | Takeda Pharmaceuticals International AG Ireland Branch | Fabry Disease | 🇪🇺 EU 2001-08-03 | Order → |
| INOmax nitric oxide | Linde Healthcare AB | Hypertension, Pulmonary; Respiratory Insufficiency | 🇪🇺 EU 2001-08-01 | Order → |
| Liprolog insulin lispro | Eli Lilly Nederland B.V. | Diabetes Mellitus | 🇪🇺 EU 2001-08-01 | Order → |
| Ceprotin human protein C | Takeda Manufacturing Austria AG | Purpura Fulminans; Protein C Deficiency | 🇪🇺 EU 2001-07-16 | Order → |
| DepoCyte cytarabine | Pacira Limited | Meningeal Neoplasms | 🇪🇺 EU 2001-07-11 | Order → |
| Ketek telithromycin | Aventis Pharma S.A. | Sinusitis; Tonsillitis; Bronchitis, Chronic; Pharyngitis; Community-Acquired Infections; Pneumonia, Bacterial | 🇪🇺 EU 2001-07-09 | Order → |
| Levviax telithromycin | Aventis Pharma S.A. | Community-Acquired Infections; Pharyngitis; Bronchitis, Chronic; Pneumonia; Tonsillitis; Sinusitis | 🇪🇺 EU 2001-07-09 | Order → |
| MabCampath alemtuzumab | Genzyme Europe B.V. | Leukemia, Lymphocytic, Chronic, B-Cell | 🇪🇺 EU 2001-07-06 | Order → |
| Nonafact human coagulation factor IX | Sanquin Plasma Products B.V. | Hemophilia B | 🇪🇺 EU 2001-07-03 | Order → |
| Aranesp darbepoetin alfa | Amgen Europe B.V. | Anemia; Cancer; Kidney Failure, Chronic | 🇪🇺 EU 2001-06-08 | Order → |
| Nespo darbepoetin alfa | Dompé Biotec S.p.A. | Kidney Failure, Chronic; Anemia; Cancer | 🇪🇺 EU 2001-06-08 | Order → |
| Ixense apomorphine | Takeda Europe R Centre Ltd. | Erectile Dysfunction | 🇪🇺 EU 2001-05-28 | Order → |
| Taluvian apomorphine | Abbott S.r.l. | Erectile Dysfunction | 🇪🇺 EU 2001-05-28 | Order → |
| Uprima apomorphine | Abbott Laboratories Ltd. | Erectile Dysfunction | 🇪🇺 EU 2001-05-28 | Order → |
| Osigraft eptotermin alfa | Olympus Biotech International Limited | Tibial Fractures | 🇪🇺 EU 2001-05-17 | Order → |
| HBVaxPro hepatitis B vaccine (recombinant DNA) | Merck Sharp & Dohme B.V. | Hepatitis B; Immunization | 🇪🇺 EU 2001-04-27 | Order → |
| Starlix nateglinide | Novartis Europharm Limited | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2001-04-03 | Order → |
| Trazec nateglinide | Novartis Europharm Ltd. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2001-04-03 | Order → |
| Targretin bexarotene | H.A.C. Pharma | Lymphoma, T-Cell, Cutaneous | 🇪🇺 EU 2001-03-29 | Order → |
| SonoVue sulphur hexafluoride | Bracco International B.V. | Ultrasonography; Echocardiography | 🇪🇺 EU 2001-03-26 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.